Review
doi: 10.1097/00007611-198409000-00027.
Pharmacologic management of Raynaud's phenomenon
- PMID: 6385288
- DOI: 10.1097/00007611-198409000-00027
Item in Clipboard
Review
Pharmacologic management of Raynaud's phenomenon
South Med J.
1984 Sep.
Abstract
Raynaud's phenomenon (RP) represents a wide spectrum of disease activity. Specific pharmacologic therapy, when indicated, should be based upon the clinician's understanding of drug effectiveness and side effects. We present an update of currently available pharmacologic agents being used for RP and review the effectiveness and side effects of these drugs.
Similar articles
-
Reserpine and Raynaud's phenomenon.N Engl J Med. 1971 Jul 29;285(5):290-1. doi: 10.1056/NEJM197107292850513. N Engl J Med. 1971. PMID: 5090401 No abstract available.
-
[Symptomatic treatment of Raynaud's phenomenon: reserpine, alpha-methyldopa, griseofulvin, guanethidine].Rev Med Liege. 1980 Oct 1;35(19):652-4. Rev Med Liege. 1980. PMID: 6161403 French. No abstract available.
-
[Spasm and Raynaud's phenomenon].Ann Cardiol Angeiol (Paris). 1981 Mar-Apr;30(2):91-3. Ann Cardiol Angeiol (Paris). 1981. PMID: 7259052 French. No abstract available.
-
[Pathophysiology and medical treatment of Raynaud's phenomena].Harefuah. 1973 Feb 15;84(4):227-8. Harefuah. 1973. PMID: 4574182 Review. Hebrew. No abstract available.
-
Raynaud's phenomenon: state of the art 1998.Scand J Rheumatol. 1998;27(5):319-22. doi: 10.1080/03009749850154311. Scand J Rheumatol. 1998. PMID: 9808392 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical